Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-07-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who have recurrent brain metastases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

NCT00006025

Brain and Central Nervous System Tumors

COMPLETED PHASE1

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

NCT01048554

Melanoma

COMPLETED PHASE2

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

NCT06410248

Recurrent Glioblastoma, IDH-Wildtype Recurrent WHO Grade 2 Glioma Recurrent WHO Grade 3 Glioma +1 more

ACTIVE_NOT_RECRUITING PHASE1

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

NCT00362817

Brain Tumor Brain Metastases

COMPLETED PHASE1/PHASE2

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

NCT01114555

Neuroblastoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the maximum tolerated dose of vinorelbine when administered in combination with temozolomide in patients with recurrent brain metastases (phase I accrual completed).
* Determine the safety and feasibility of this treatment regimen in these patients.
* Determine the efficacy of this treatment regimen, in terms of objective radiographic response and overall and progression-free survival, in these patients.

OUTLINE: This is a dose-escalation study of vinorelbine.

Patients receive vinorelbine IV over 5-10 minutes on days 1 and 8 and oral temozolomide once daily on days 1-7 and 15-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of vinorelbine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 20-35 patients will be treated at that dose level.

Patients are followed every 3-4 months.

PROJECTED ACCRUAL: A minimum of 3 patients will be accrued for the phase I portion of this study and 20-35 patients will be accrued for the phase II portion of this study within 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Temozolomide and Vinorelbine

Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.

Group Type EXPERIMENTAL

temozolomide

Intervention Type DRUG

vinorelbine tartrate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

temozolomide

Intervention Type DRUG

vinorelbine tartrate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> or = 18 years.
* Karnofsky performance score \> or = 60.
* Histopathologic confirmation of the diagnosis of a solid tumor malignancy. The brain metastasis diagnosis per se does not have to be pathologically confirmed if the clinical and neuro radiographic picture is typical.
* MRI (or CT if the patient cannot undergo MRI) evidence of evaluable disease in the brain.
* Absolute neutrophil count \> or = 1,500/mm³. Platelet count \> or = 100,000/mm³.
* Hemoglobin \> or = 10 g/dl.
* BUN and serum creatinine both \< 1.5 times upper limit of normal.
* Total and direct bilirubin both \< 1.5 times upper limit of normal.
* SGOT and SGPT both \< or = 3 times upper limit of normal.
* Alkaline phosphatase \< or = 2 times upper limit of normal.
* At least two weeks must have elapsed from brain biopsy, craniotomy, or other surgery.
* Life expectancy \> or = 8 weeks.
* Patient or their legal guardian or legal next-of-kin must provide written informed consent prior to patient's registration on study.
* At least four weeks must have elapsed from previous external beam radiation therapy, or eight weeks from stereotactic radiosurgery.
* Patients treated with radiosurgery should have evidence of progression at a distant site in the brain, or confirmation of tumor progression by biopsy or PET scan.

Exclusion Criteria

* Previous treatment with temozolomide, dacarbazine or vinorelbine.
* Patients who have not recovered from all acute toxicities of prior therapies.
* Patients with evidence of leptomeningeal metastases or primary dural metastases.
* Patients who are poor medical risks because of nonmalignant systemic disease, as well as those with acute infection requiring treatment with intravenous antibiotics.
* Patients whose psychiatric condition would, in the judgment of the principal investigator, make it unlikely that they could adhere to the requirements of the protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No